• Educational resources
  • Events
  • Expert Panel
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ItalyChange country/region
Type 2 Inflammation

ADVENT at ISDS 2023: Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

Highlights from the ADVENT symposium at the Inflammatory Skin Disease Summit (ISDS) 2023 exploring the role of type 2 inflammation in atopic dermatitis.
Lisa Beck
Robert Bissonnette
Gil  Yosipovitch
MD
Lisa Beck +2 more
Past event
16November2023
Location
Aula der Wissenschaften
Wollzeile 27a A-1010 Vienna Austria

Learning objectives

  • Review the latest evidence on how type 2 inflammation drives skin barrier dysfunction in AD
  • Discuss the evidence illustrating how type 2 inflammation affects the skin microbiome in AD
  • Explore the role of type 2 inflammation in neuroimmune axis dysregulation in AD

Description

At the ADVENT symposium at the 2023 Inflammatory Skin Disease Summit entitled “Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch”, experts Lisa A. Beck, MD (University of Rochester Medical Center, USA); Robert Bissonnette, MD (Innovaderm Research Inc., Canada); and Gil Yosipovitch, MD (University of Miami, USA) discussed the latest advances in understanding how type 2 inflammation drives skin barrier dysfunction, dysbiosis and itch in atopic dermatitis (AD).

 

Location

Aula der Wissenschaften
Wollzeile 27a A-1010 Vienna Austria
Tags
expert insightsmechanism of diseasesymposium
MAT-GLB-2303613 v1 11/2023

Speakers

Dermatology
MD

Lisa Beck

Goldsmith Professor of Dermatology, University of Rochester Medical Center, New York, United States.

Dermatology
MD

Robert Bissonnette

President of Innovaderm Research, Montréal, Quebec, Canada

Dermatology
MD

Gil Yosipovitch

Professor and Stiefel-endowed Chair of Medical Dermatology at the Dr. Phillip Frost Department of Dermatology at the Miller School of Medicine at the University of Miami; Director of the Miami Itch Center, Florida, US